首页> 美国卫生研究院文献>Saudi Journal of Biological Sciences >FbD directed fabrication and investigation of luliconazole based SLN gel for the amelioration of candidal vulvovaginitis: a 2 T (thermosensitive transvaginal) approach
【2h】

FbD directed fabrication and investigation of luliconazole based SLN gel for the amelioration of candidal vulvovaginitis: a 2 T (thermosensitive transvaginal) approach

机译:基于Luliconazole的SLN凝胶的FBD定向制作和研究候选外阴炎的改善:A 2 T(热敏和变性经变性)方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Candidal vulvovaginitis (CVV), is the second most leading vaginal infection (global prevalence > 75%), caused due to excessive growth of Candida spp., predominantly Candida albicans (>95% cases). The current treatment regimens for CVV are marred with the challenges of fungal resistance & infection recurrence, subsequently leading to the compromised therapeutic efficacy of anti-fungal drugs, prolonged treatment and low patient compliance. The core of the present research was the fabrication & investigation of 2 T-SLN (solid lipid nanoparticles) gel carrying luliconazole for the amelioration of CVV. ‘2T’ symbolizes transvaginal & thermosensitive attributes of the present formulation. SLNs were prepared by a modified melt emulsification-ultra sonication method using a combination of solid lipids (Gelucire 50/13 & Precirol ATO 5), surfactant (Tween 80) and co-surfactant (Kolliphor). Formulation by design (FbD) approach was adopted to obtain appropriately screened and tailored SLNs. The optimized SLNs yielded a particle size, polydispersity index & entrapment efficiency of 62.18 nm, 0.263 & 81.5% respectively. To formulate the 2 T-gel, the final SLNs were loaded into Carbopol 971P-NF and Triethanolamine based gel. The 2 T-SLN gel was found to be easily spreadable and homogenous with mean extrudability (15 ± 0.4 g/cm2), viscosity (696.42 ± 2.34 Pa·s) and %drug content (93.24 ± 0.73%) values.. The pH of the prepared 2 T-SLN gel (4.5 ± 0.5) was in concordance with the vaginal pH (normal conditions). For in-vitro characterization of an optimized 2 T-SLN gel the release kinetics & anticandidal activity were assessed which offers a %cumulative drug release of 62 ± 0.5% in 72 h and 37.3 ± 1.5 mm zone of inhibition in 48 h. The visual appearance & dimensions were determined using fluorescent microscopy (spherical shape) & transmission electron microscopy (90–120 nm) respectively. The optimized 2 T-SLN gel showcases a skin-friendly profile with no significant signs of erythema and oedema and was found to be stable at room temperature for 2 months without any visual non-uniformity/cracking/breaking. In conclusion, the current research serves a new therapeutic perspective in assessing the activity of luliconazole for vaginal drug delivery using a 2 T-SLN gel system.
机译:候选潜伏期炎(CVV)是第二次致命的阴道感染(全球患病率> 75%),由于Candida SPP过度生长引起的。,主要是念珠菌(> 95%案例)。 CVV的目前治疗方案与真菌抗性和感染复发的挑战造成的,随后导致抗真菌药物的受损治疗疗效,延长治疗和低患者依从性。本研究的核心是2 T-SLN(固体脂质纳米颗粒)凝胶携带Luliconazole的制造和研究,用于CVV的改善。 '2T'象征着本制定的经透视和热敏属性。通过使用固体脂质的组合(Gelucire 50/13和前导5),表面活性剂(Tween80)和共表面活性剂(Kolliphor)的改性熔融乳化 - 超超声处理方法制备SLN。采用设计配方(FBD)方法获得适当筛选和量身定制的SLN。优化的SLNS分别产生62.18nm,0.263&81.5%的粒度,多分散指数和夹带效率。为了配制2 T-凝胶,将最终的SLNS加载到Carbopol 971P-NF和三乙醇胺基凝胶中。发现2个T-SLN凝胶易于涂布和均匀,平均挤出性(15±0.4g / cm 2),粘度(696.42±2.34 pa·s)和%药物含量(93.24±0.73%)。pH值制备的2个T-SLN凝胶(4.5±0.5)与阴道pH(正常条件)相一致。对于优化的2 T-SLN凝胶的体外表征,评估释放动力学和反恶毒物活性,其在42小时内为72小时的累积药物释放量%62±0.5%和37.3±1.5mm的抑制区。使用荧光显微镜(球形)和透射电子显微镜(90-120nm)测定视觉外观和尺寸。优化的2 T-SLN凝胶展示了一种皮肤友好的型材,没有明显的红斑和水肿的重要迹象,发现在室温下稳定2个月,没有任何视觉不均匀/开裂/破裂。总之,目前的研究在评估使用2 T-SLN凝胶系统的阴道药物递送的兰西尼亚唑的活性方面提供了新的治疗性观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号